The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 26, 2024

Filed:

May. 15, 2018
Applicant:

Alx Oncology Inc., South San Francisco, CA (US);

Inventors:

Marija Vrljic, San Mateo, CA (US);

Jaume Pons, San Francisco, CA (US);

Assignee:

ALX ONCOLOGY INC., South San Francisco, CA (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01); C07K 14/47 (2006.01); C07K 14/52 (2006.01); C07K 14/54 (2006.01); C07K 16/32 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2863 (2013.01); A61P 35/00 (2018.01); C07K 14/47 (2013.01); C07K 14/52 (2013.01); C07K 14/5428 (2013.01); C07K 14/5434 (2013.01); C07K 16/2818 (2013.01); C07K 16/32 (2013.01); A61K 2039/505 (2013.01); C07K 2317/31 (2013.01); C07K 2317/41 (2013.01); C07K 2317/55 (2013.01); C07K 2317/62 (2013.01); C07K 2317/76 (2013.01); C07K 2319/01 (2013.01); C07K 2319/30 (2013.01); C07K 2319/50 (2013.01);
Abstract

The present application provides activatable antibodies comprising an antibody comprising an antigen-binding domain (ABD), wherein the ABD comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the N-terminus of the VH is fused to a first polypeptide shield moiety (S1), and the N-terminus of the VL is fused to a second polypeptide shield moiety (S2), wherein S1 comprises a first disease-sensing releasable moiety (DS1) and/or S2 comprises a second disease-sensing releasable moiety (DS2), wherein association of S1 with S2 blocks binding of the ABD to its target, and wherein the ABD does not specifically bind to S1, S2, or association thereof. Composition, methods of treatment using the activatable antibodies, and methods of preparation thereof are further provided.


Find Patent Forward Citations

Loading…